History
Advances in virology, neuroscience, and nanomedicine have expanded our understanding of how viruses can affect the brain. By examining key developments in antiviral research, blood-brain barrier science, and targeted drug delivery, the foundation for predictive neuroprotection systems like NeuroShield becomes clearer.
1954 | Early research documents viral invasion of the central nervous system, including studies on polio and herpes viruses
1970s | Blood-brain barrier (BBB) structure and selective permeability become widely studied in neuroscience
1982 | Antiviral therapy acyclovir is approved by the FDA for treating herpes infections
2003 | SARS-CoV outbreak increases global focus on the systemic and neurological effects of viral infections
2010 | Advances in nanoparticle-based drug delivery accelerate research into targeted therapeutic systems
2020 | COVID-19 (SARS-CoV-2) highlights widespread neurological symptoms associated with viral infection
2020 | Neuropilin-1 (NRP1) is identified as a potential co-factor involved in SARS-CoV-2 cell entry
Future | Advances in biosurveillance, artificial intelligence, and targeted drug delivery are shaping the development of predictive systems designed to address neurological risk earlier. NeuroShield represents this approach by combining real-time analysis with targeted intervention at the blood-brain barrier to help reduce the likelihood of viral neuroinvasion.